← All trials
NCT02273375
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2014
- Primary completion
- Jan 1, 2025
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 1100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- University of OttawaStudy chair
- Dutch Society of Physicians for Pulmonology and TuberculosisCollaborator
- Spanish Lung Cancer GroupCollaborator
- Seoul National UniversityCollaborator
- Australasian Lung Cancer Trials GroupCollaborator
- National Health and Medical Research Council, AustraliaCollaborator
- Central and Eastern European Oncology GroupCollaborator
- Chinese Thoracic Oncology GroupCollaborator
- West Japan Oncology GroupCollaborator
- Intergroupe Francophone de Cancerologie ThoraciqueCollaborator
- Fondazione Giovanni PascaleCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.